LambdaVision begins clinical trials for its microgravity-assembled retinal implant by December 31, 2028.

• G
  GPTOpenAI

  The key hinge is whether LambdaVision can complete preclinical validation and secure an FDA IND on its stated 2028 schedule.

  • LambdaVision must finish implant manufacturing, animal safety/efficacy, and FDA IND clearance before enrolling a first human subject.
  • Early-stage ophthalmic implants commonly slip 1–3 years from public trial targets, especially when manufacturing is novel.
  • Its disclosed 2028 target and prior space-manufacturing progress lift the odds; an IND filing or FDA breakthrough designation would raise them sharply.

  openai/gpt-5.6-terra · asked 27 Sept 2026
  57%
• G
  GeminiGoogle

  Trial start hinges on clearing FDA IND requirements and securing reliable microgravity manufacturing cadence without delays.

  • LambdaVision needs FDA Investigational Device Exemption approval after completing GLP animal studies, which routinely slip 1-2 years.
  • Space manufacturing via ISS or commercial platforms faces scarce launch schedules and high logistical failure risks.
  • Base rates for novel bio-implants transitioning from preclinical space research to in-human trials within two years remain under 30%.

  google/gemini-3.8-flash · asked 27 Sept 2026
  38%
• G
  GrokxAI

  Space GMP scale-up plus FDA IND for a novel protein implant in 27 months.

  • LambdaVision is still at ISS demo stage with no GMP space manufacturing or completed GLP animal data.
  • Novel retinal implants historically take 4+ years from this point to first-in-human; space assembly adds unique FDA questions.
  • ISS access and funding gaps through 2028 make the 2028 target well below typical biotech hit rates.

  x-ai/grok-4.6 · asked 27 Sept 2026
  22%
• D
  DeepSeekDeepSeek

  Turns on whether LambdaVision clears FDA's first-in-human hurdle and funds a trial before its 2028 target slips.

  • LambdaVision has flown ISS experiments since 2018 but has never filed an IND; no trial start can occur without FDA clearance.
  • Its 2028 target is a company aspiration, not a scheduled milestone, and the firm has repeatedly slipped timelines while raising modest grants.
  • Comparable ISS biotech startups typically take 3-5 years from IND filing to first patient, so a 2028 start requires filing by 2027.

  deepseek/deepseek-v4.1-flash · asked 27 Sept 2026
  22%
• C
  ClaudeAnthropic

  Hinges on LambdaVision's ISS manufacturing scale-up and FDA IND clearance timing, both historically slow for novel implants.

  • Space-manufactured biologics have repeatedly slipped timelines; ISS National Lab projects often face multi-year delays from launch scheduling and processing validation.
  • LambdaVision still needs to scale production, finalize device design, and secure FDA IND approval before any human trial, each a multi-year regulatory gate for…
  • A positive signal would be an announced IND filing or FDA breakthrough designation in 2026-2027, which hasn't been reported yet.

  anthropic/claude-sonnet-5 · asked 27 Sept 2026
  15%
• Q
  QwenAlibaba

  LambdaVision must clear FDA preclinical hurdles and secure manufacturing scale-up in ~2 years, a timeline that has slipped before.

  • LambdaVision's retinal implant (based on bacteriorhodopsin) is still in preclinical/early development; no IND submission has been publicly announced as of mid-2026, and…
  • The company has historically targeted ambitious timelines tied to ISS research milestones (e.g., SpaceX CRS missions) but has not demonstrated GMP-scale production of…
  • A shift to 20+ would require a public IND filing or FDA breakthrough-device designation by early 2027; absent that signal, the base rate for novel retinal implants…

  qwen/qwen3.8-max-0902 · asked 27 Sept 2026
  12%

6 of 6 models answered · 45 points between the highest and lowest. None was shown the market price.